Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...
In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...
In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss ...
ACT: At this year’s SCRS Summit, several site representatives raised concerns about overly complex protocols and patient ...
How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...
You have medical affairs being more involved on the research side, engaging with these HCPs to try to create referral ...
FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...
Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...
The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...
Understand how combining proprietary and real-world datasets with tokenization enables accurate protocol matching while ...
In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...
In today’s ACT Brief, we look at how adaptive trial models are reshaping precision medicine, new data showing Wegovy’s impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback